This post was originally published on this site Prophylactic anti-TNF therapy improves the safety and, to some degree, the efficacy of checkpoint blockade combination immunotherapies, a mouse study says. The findings of the study, “Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy,” were published in Nature. Previous studies have shown…
This post was originally published on this site New research using “big data” helps highlight the differences between breast cancer cell lines and actual patient samples. This could allow researchers to choose models that more accurately reflect what actually happens in people. The study, “Evaluating cell lines as models for metastatic breast cancer through integrative…
This post was originally published on this site A non-invasive test that examines microRNAs — small RNA molecules — in urine may be used to identify aggressive prostate cancers with great accuracy, potentially avoiding unnecessary treatments for slow-growing cancers, a study suggests. The study, “Temporal stability and prognostic biomarker potential of the prostate cancer urine…
This post was originally published on this site In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research program. Called the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Program (UKMRA-Myeloma UK-CARP), the grant initiative seeks to build upon the success of…
This post was originally published on this site A new international consortium based in Paris, and funded largely by the 28-member European Union, intends to speed the diagnosis of rare diseases, while also accelerating the development of treatments for the 95% of such illnesses that currently don’t have one. The European Joint Programme on Rare…
This post was originally published on this site Certain patients with primary central nervous system (PCNS) lymphoma, a rare type of brain cancer, may benefit more from having surgery to remove their tumor than following the current standard of care, which does not include surgery, a review of studies concludes. Until now, surgical resection has…
This post was originally published on this site The potential oral therapy TRC253 was well-tolerated and showed effectiveness in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the first part of a Phase 1/2a clinical trial. The second part of the study (NCT02987829) is currently enrolling at several U.S. locations…
This post was originally published on this site A blood test successfully identified ovarian cancer from circulating cells, and may enable this cancer to be detected early and prior to surgery, results of the first phase of a clinical verification study show. This first stage or pre-study was conducted at the University of Rochester Medical Center…
This post was originally published on this site Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a faster and easier treatment for people with multiple myeloma. Currently, Darzalex is approved as an intravenous infusion into a vein that takes several hours. The biologics license…
This post was originally published on this site Transgene has completed patient enrollment for its Phase 2 trial evaluating the cancer vaccine TG4010 in combination with Opdivo (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with low or no expression of PD-L1. The first results regarding the trial’s…
